https://www.selleckchem.com/products/gdc-0084.html
The MTD of alpelisib in arm B was 350 mg given 4 days on, 3 days off. Among 17 patients assessed, 1 had a partial response, 14 had stable disease, and 2 had disease progression at best response. Five patients had stable disease for 30 weeks. mRNA profiling of pre- and on-treatment tissue demonstrated target engagement by alpelisib via induction of downstream signaling and feedback pathways. Combination treatment with alpelisib, trastuzumab, and LJM716 was limited by gastrointestinal toxicity. Further efforts are warranted to target
Like
Comment
Share
